Cat. #153267
Anti-CD70 [BU69] rAb
Cat. #: 153267
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: CD70
Class: Recombinant
Application: FACS ; IHC ; IP
Reactivity: Human
Host: Mouse
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Roy Jefferis
Institute: Absolute Antibody ; University of Birmingham
Tool Details
*FOR RESEARCH USE ONLY
- Name: Anti-CD70 [BU69] rAb
- Alternate name: CD7 Molecule; Tumor Necrosis Factor Ligand Superfamily Member 7; CD27 Ligand; CD27LG; TNFSF7; CD27L; Tumor Necrosis Factor Ligand 8A; Surface Antigen CD7; Ki-24 Antigen; CD7 Antigen; TNLG8A
- Clone: BU69
- Tool sub type: Primary antibody
- Class: Recombinant
- Conjugation: Unconjugated
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IP
- Description: CD70 is a 30kDa ligand of the receptor CD27. Both belong to the tumour necrosis factor receptor superfamily 7. Receptor activation can induce proliferation and apoptosis. BU69 inhibits T cell proliferation induced by dendritic cells.
- Immunogen: Waldenstroms macroglobulineamia cell line WM-1
- Isotype: IgG1
- Recommended controls: Raji cells
Target Details
- Target: CD70
- Tissue cell line specificity: Raji cells
- Target background: CD70 is a 30kDa ligand of the receptor CD27. Both belong to the tumour necrosis factor receptor superfamily 7. Receptor activation can induce proliferation and apoptosis. BU69 inhibits T cell proliferation induced by dendritic cells.
Applications
- Application: FACS ; IHC ; IP
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS
- Shipping conditions: Shipping at 4° C
References
- Original hybridoma first published in: Ito et al. 1999. J Immunol. 163(3):1409-19. PMID: 10415041.